한빛사 논문
Mengzhao Xue1,*, Chung Sub Kim1,2,*, Alan R. Healy1,2,†, Kevin M. Wernke1, Zhixun Wang1,‡, Madeline C. Frischling1, Emilee E. Shine2,3, Weiwei Wang4,5, Seth B. Herzon1,6,§, Jason M. Crawford1,2,3,§
1 Department of Chemistry, Yale University, New Haven, CT 06520, USA.
2 Chemical Biology Institute, Yale University, West Haven, CT 06516, USA.
3 Department of Microbial Pathogenesis, Yale School of Medicine, New Haven, CT 06536, USA.
4 Department of Molecular Biophysics and Biochemistry, Yale School of Medicine, New Haven, CT 06520, USA.
5 W. M. Keck Biotechnology Resource Laboratory, Yale School of Medicine, New Haven, CT 06510, USA.
6 Department of Pharmacology, Yale School of Medicine, New Haven, CT 06520, USA.
* These authors contributed equally to this work.
† Present address: New York University Abu Dhabi, Post Office Box 129188, Abu Dhabi, United Arab Emirates.
‡ Present address: Department of Process Research and Development, Merck, Rahway, NJ 07065, USA.
§ Corresponding author : Seth B. Herzon, Jason M. Crawford
Abstract
Colibactin is a complex secondary metabolite produced by some genotoxic gut Escherichia coli strains. The presence of colibactin-producing bacteria correlates with the frequency and severity of colorectal cancer in humans. However, because colibactin has not been isolated or structurally characterized, studying the physiological effects of colibactin-producing bacteria in the human gut has been difficult. We used a combination of genetics, isotope labeling, tandem mass spectrometry, and chemical synthesis to deduce the structure of colibactin. Our structural assignment accounts for all known biosynthetic and cell biology data and suggests roles for the final unaccounted enzymes in the colibactin gene cluster.
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기